Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Terano Tapped as President of Japan Vaccine
June 2, 2016
- Chugai Licenses Antibody SA237 to Roche, Japan Filing Slated for 2018
June 2, 2016
- Ex-Boehringer Japan Pres. Torii to Head Novartis Holdings Japan
June 2, 2016
- After Tax Hike Delay, Industry Officials Vigilant about Price Slash for Innovative Drugs
June 2, 2016
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
June 1, 2016
- Daiichi Sankyo Ceases Development of Patritumab for NSCLC
June 1, 2016
- Oncolys Concludes Option Agreement with US CRO for HIV Treatment Censavudine
June 1, 2016
- Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
May 31, 2016
- Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
- Takeda’s Myeloma Drug Hopeful Ninlaro Rebuffed by CHMP
May 31, 2016
- Takeda Gets CHMP’s Positive Opinion for New Adcetris Indication
May 31, 2016
- Mylan Japan Labor Union, Management Reach Settlement; All 14 Members to Leave on May 31
May 30, 2016
- Ethical Drug Sales Up 6.1% in March: Crecon Report
May 30, 2016
- Application Filing Expected in FY2018 for Cancer Peptide Vaccine Originating from Kurume Univ.
May 30, 2016
- Kyorin to Exclusively Market MSD’s Desloratadine in Japan
May 27, 2016
- Astellas Grants Thunderbolt Pharma Rights for BAFF/APRIL Dual Antagonist Program
May 26, 2016
- Eisai Rolls Out AMPA Receptor Antagonist Fycompa
May 26, 2016
- AZ Launches Tagrisso for Treatment of NSCLC
May 26, 2016
- Shionogi’s Naldemedine Delivers Positive Results in Global PIII
May 25, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…